Funobactam is under clinical development by Evopoint Bioscience and currently in Phase III for Hospital Acquired Pneumonia (HAP). According to GlobalData, Phase III drugs for Hospital Acquired Pneumonia (HAP) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Funobactam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XNW-4107 is under development for the treatment of Gram-negative bacterial infections, urinary tract infections, hospital acquired and ventilator associated pneumonia. The drug candidate acts by targeting beta-lactamase. It is administered by intravenous route.
Evopoint Bioscience overview
Evopoint Bioscience, formerly Suzhou Sinovent Pharmaceuticals, is a biopharmaceutical company that involved in development of therapeutics for oncology, autoimmunity, and infectious diseases. The company is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Funobactam’s drug-specific PTSR and LoA scores, buy the report here.